+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer



The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer



Oncology 87(4): 205-214



The aim of the present study was to evaluate the superiority of the high-sensitivity modified Glasgow prognostic score (HS-mGPS) before surgery in patients with gastric cancer. The participants of this retrospective study comprised 552 patients with gastric cancer who underwent gastrectomy at the Fukuoka University Hospital. The HS-mGPS was calculated before surgery based on cutoff values of 0.3 mg/dl for C-reactive protein and 3.5 g/dl for albumin, and correlations between the HS-mGPS and the clinicopathological parameters and prognosis were evaluated. In addition, the superiority of the HS-mGPS to the mGPS as a prognostic indicator was examined in detail. The mGPS was 0 in 494 patients, 1 in 24 patients and 2 in 34 patients. In contrast, the HS-mGPS was 0 in 411 patients, 1 in 75 patients and 2 in 66 patients. Both the mGPS (p < 0.0001) and HS-mGPS (p < 0.0001) were good prognostic predictors in gastric cancer patients who underwent gastrectomy. Of the 494 patients with an mGPS of 0 before surgery, 51 and 32 exhibited an HS-mGPS of 1 and 2, respectively. The patients who exhibited migration in the HS-mGPS demonstrated a significantly more unfavorable prognosis than the patients with an HS-mGPS of 0 (p < 0.0001). The prognostic impact of the HS-mGPS was especially clear in stage I and IV patients (p = 0.0027, p = 0.017). The HS-mGPS was found to be a superior prognostic predictor compared to the mGPS in a multivariate analysis (p = 0.0002). The HS-mGPS before surgery is a superior prognostic predictor in patients with gastric cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056357925

Download citation: RISBibTeXText

PMID: 25034097

DOI: 10.1159/000362601


Related references

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer. Oncotarget 9(97): 37008-37016, 2019

Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer. Journal of Cancer Research and Therapeutics 12(2): 945-951, 2017

Prognostic Value of the Glasgow Prognostic Score or Modified Glasgow Prognostic Score for Patients with Colorectal Cancer Receiving Various Treatments: a Systematic Review and Meta-Analysis. Cellular Physiology and Biochemistry 51(3): 1237-1249, 2018

The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma. Oncotarget 7(41): 67485-67494, 2016

Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy. Zhonghua Zhong Liu Za Zhi 39(3): 195-200, 2017

Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 142(6): 1285-1297, 2017

Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer. Journal of Gastroenterology 49(6): 1040-1046, 2015

High-sensitivity modified Glasgow prognostic score (HS-mGPS) Is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy. Oncotarget 8(59): 99861-99870, 2017

Improvement of high-sensitivity inflammation-based Glasgow prognostic score by gastrectomy is a favorable prognostic factor in patients with gastric cancer. Anticancer Research 34(10): 5695-5702, 2014

Glasgow Prognostic Score is superior to ECOG PS as a prognostic factor in patients with gastric cancer with peritoneal seeding. Oncology Letters 15(4): 4193-4200, 2018

Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy. International Journal of Clinical and Experimental Pathology 8(5): 5273-5281, 2016

A prognostic indicator of survival in metastatic colorectal cancer patients in the era of molecular-targeted agents: the modified Glasgow Prognostic Score. Oncology 86(1): 44-45, 2014

Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?. Journal of Surgical Oncology 113(7): 732-737, 2017

Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. Urologic Oncology 2018, 2018

The value of the high-sensitivity modified Glasgow prognostic score in predicting the survival of patients with a soft-tissue sarcoma. Bone and Joint Journal 97-B(6): 847-852, 2015